In a mouse model of pancreatic cancer, the density of the ECM was shown to be reduced after an anti-CD40 agonist treatment, through the activation of matrix metalloproteinases production by TAM, which may facilitate the motility of T cells (59). This evidence concerns the gene CD40 and pancreatic neoplasm.